Clinical Trial Update: Treatment With Azacitidine of Recurrent Gliomas With IDH1/2 Mutation [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating azacitidine in recurrent gliomas with IDH1/2 mutation.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Idh1 2 Mutated Glioma

Drugs mentioned

• AZACITIDINE (AZACITIDINE)

Snippet

Sponsor: Assistance Publique - Hôpitaux de Paris | Conditions: Recurrent IDH1/2 Mutated Glioma | Phase 2 | Status: UNKNOWN